<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544748</url>
  </required_header>
  <id_info>
    <org_study_id>APD-SMG-I</org_study_id>
    <nct_id>NCT04544748</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies</brief_title>
  <official_title>A Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 (GENERIUM JSC, Russia) in Subjects With Solid Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AO GENERIUM</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AO GENERIUM</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety,&#xD;
      Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects&#xD;
      with Advanced Solid Malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GNR-051 is a monoclonal antibody, targeting the Programmed Death-1 (PD-1) membrane receptor&#xD;
      on T lymphocytes and other cells of the immune system. The anti-PD-1 antibody, preventing the&#xD;
      binding of the PD-1 receptor with the ligands PD-L1 and PD-L2, reactivates the pool of&#xD;
      tumor-specific cytotoxic T-lymphocytes in the tumor microenvironment and, thus, reactivates&#xD;
      the antitumor immunity. GNR-051 is able to block the signaling molecule PD-1, which&#xD;
      suppresses the antitumor immune response, for the treatment of cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 Days</time_frame>
    <description>Tolerability of GNR-051</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicity (DLT)</measure>
    <time_frame>28 Days</time_frame>
    <description>Tolerability of GNR-051</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>36 Months</time_frame>
    <description>Safety profile of GNR-051; All adverse events (CTCAE 5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>36 Months</time_frame>
    <description>Safety profile of GNR-051; All adverse events (CTCAE 5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical examination</measure>
    <time_frame>36 Months</time_frame>
    <description>Safety profile of GNR-051; All adverse events (CTCAE 5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-lead electrocardiogram</measure>
    <time_frame>36 Months</time_frame>
    <description>Safety profile of GNR-051; All adverse events (CTCAE 5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECOG assessment</measure>
    <time_frame>36 Months</time_frame>
    <description>Safety profile of GNR-051; All adverse events (CTCAE 5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antidrug antibody</measure>
    <time_frame>36 Months</time_frame>
    <description>Safety profile of GNR-051; All adverse events (CTCAE 5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GNR-051 Serum Concentration</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters GNR-051</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax - Maximum serum concentration after the 1st administration</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin - Minimum serum concentration after the 1st administration</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax - Time to peak serum concentration after the 1st administration</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ - Half-life after the 1st administration,</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL - Clearance after the 1st administration</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - Area Under the Curve after the 1st administration</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax, SS - Time to peak serum concentration at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSS - serum concentration at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, SS - Maximum serum concentration at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLSS - Clearance at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin, SS - serum concentration at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd, SS - Volume of distribution at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAUCτ 0-t - Area under the concentration time-curves from zero to the end of the dosing interval at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,ss - Half-life at steady state</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ - Area under the concentration time-curves from time zero to infinity after last administration</measure>
    <time_frame>36 Months</time_frame>
    <description>PharmacoCkinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index (Rac; steady-state AUC0-τ/single-dose AUC0-τ)</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach steady state - elimination half-life</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacokinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-1 receptor occupancy rate (%) in peripheral blood mononuclear cells (PBMCs)</measure>
    <time_frame>6 Months</time_frame>
    <description>Pharmacodynamic parameters GNR-051</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Objective Response Rate (ORR) - best response of complete remission (CR) or partial remission (PR) according to RECIST 1.1 and IRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best objective response rate (complete response (CR) + partial response (PR))</measure>
    <time_frame>36 Months</time_frame>
    <description>Best objective response rate (complete response (CR) + partial response (PR)) according to RECIST 1.1 and IRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>36 Months</time_frame>
    <description>Progression-Free Survival (PFS) - time from 1st dose administration to progression according to RECIST 1.1 or until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Disease Control Rate (DCR) - percentage of patients who have achieved complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Best Overall Response (BOR) - the best response recorded from the 1st dose administration until the disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Duration of response - the length of time that a tumor continues to respond to treatment without the cancer growing or spreading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>36 Months</time_frame>
    <description>Overall Survival (OS) - time from enrollment to the date of death</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Malignant Melanoma (MEL)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-051 (0.1 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-051 (0.3 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-051 (1 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-051 (3 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>GNR-051 (10 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GNR-051</intervention_name>
    <description>Anti-PD1 monoclonal antibody</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent Form and the subject's ability to follow the Protocol&#xD;
             requirements;&#xD;
&#xD;
          -  Age: 18 years and older at the signing of the informed consent;&#xD;
&#xD;
          -  Histologically confirmed metastatic solid malignant tumors (non-small cell lung&#xD;
             cancer, renal cell carcinoma, melanoma), refractory or recurrent after one or more&#xD;
             courses of previous therapy and not subject to surgical treatment and radiation&#xD;
             therapy. Melanoma - regardless of the presence and success of previous treatment;&#xD;
&#xD;
          -  ECOG performance status ≤ 2;&#xD;
&#xD;
          -  At least one RESICT 1.1-defined measurable target lesion;&#xD;
&#xD;
          -  Completion of the previous drug treatment of the underlying disease (if applicable) at&#xD;
             least 28 days before the first administration of GNR-051;&#xD;
&#xD;
          -  Resolution or stabilization of toxicity manifestations of previous radiation or&#xD;
             chemotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with anti-CTLA4 and/or anti-PD-1/PD-L1/PD-L2 agents;&#xD;
&#xD;
          -  Hypersensitivity to any of the components of GNR-051;&#xD;
&#xD;
          -  Progression (growth of previous, appearance of new) metastases in the brain and&#xD;
             meninges, identified by CT or MRI, in a period of less than 56 days before the first&#xD;
             administration of GNR-051; worsening of neurological symptoms in a patient with&#xD;
             metastases in the brain or meninges within a period of less than 28 days before the&#xD;
             first administration of GNR-051; or continued treatment of metastases in the brain or&#xD;
             meninges with glucocorticosteroids (GCS) for a period of less than 14 days before the&#xD;
             first administration of GNR-051 (except for a maintenance daily dose of GCS equivalent&#xD;
             to 10 mg of prednisolone);&#xD;
&#xD;
          -  Inability to conduct a biopsy according to the protocol;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;50% (EchoCG);&#xD;
&#xD;
          -  The need to use anticancer drugs, other than the investigated one, for at least 3&#xD;
             months after the first administration of the drug;&#xD;
&#xD;
          -  Patients who need radiotherapy or surgical therapy;&#xD;
&#xD;
          -  Previous radiotherapy ended &lt;28 days before the first dose administration;&#xD;
&#xD;
          -  Previous stereotactic radiation therapy ended &lt;14 days before the first dose&#xD;
             administration;&#xD;
&#xD;
          -  Therapeutic use of radiopharmaceuticals ≤56 days prior to first dose administration;&#xD;
&#xD;
          -  Patients who have received another experimental drug (not registered in Russia) within&#xD;
             28 days or 5 half-lives of the experimental drug before the first administration&#xD;
             GNR-051;&#xD;
&#xD;
          -  Patients who have received vaccines against infectious diseases (eg influenza virus)&#xD;
             within 28 days before the first administration of the drug;&#xD;
&#xD;
          -  Patients who have received narcotic analgesics &lt;14 days before the first&#xD;
             administration of GNR-051;&#xD;
&#xD;
          -  Surgery with general anesthesia &lt;28 days before the first administration of GNR-051.&#xD;
&#xD;
          -  Surgery with regional / epidural anesthesia &lt;72 hours and / or not all post-anesthetic&#xD;
             AEs resolved before the first administration of GNR-051;&#xD;
&#xD;
          -  Laboratory parameters:&#xD;
&#xD;
               -  Absolute leukocyte count &lt;2000 / μL;&#xD;
&#xD;
               -  Absolute neutrophil count &lt;1500 / μL;&#xD;
&#xD;
               -  Absolute platelet count &lt;100 × 103 / μL;&#xD;
&#xD;
               -  Hemoglobin level &lt;9.0 g / dL;&#xD;
&#xD;
               -  Creatinine&gt; 2 mg / dL;&#xD;
&#xD;
               -  AST&gt; 2.5 × the upper limit of normal (ULN) in the absence of liver metastases,&#xD;
                  or&gt; 5 × ULN with the liver metastases;&#xD;
&#xD;
               -  ALT &gt; 2.5 × ULN in the absence of liver metastases, or&gt; 5 × ULN with the liver&#xD;
                  metastases;&#xD;
&#xD;
               -  Total bilirubin&gt; 2 × ULN;&#xD;
&#xD;
          -  Systemic autoimmune diseases (including but not limited to SLE, Crohn's disease,&#xD;
             ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective&#xD;
             tissue disease, overlap syndrome, etc.);&#xD;
&#xD;
          -  Concomitant cancer (except for basal or squamous cell carcinoma of the skin,&#xD;
             superficial bladder cancer, carcinoma in situ of the cervix, prostate, or breast);&#xD;
&#xD;
          -  Patients who need therapy with corticosteroids or other immunosuppressants;&#xD;
&#xD;
          -  Systemic therapy with corticosteroids or immunosuppressants for ≤7 days before the&#xD;
             first administration GNR-051;&#xD;
&#xD;
          -  Any other concomitant condition (e.g., medical condition, mental disorders,&#xD;
             alcohol/drug abuse) that constitutes an unacceptable risk to the patient's health&#xD;
             during the investigational therapy or prevents a patient from following the Protocol&#xD;
             procedures;&#xD;
&#xD;
          -  Active HBV/HCV/HIV infection;&#xD;
&#xD;
          -  Pregnant or lactating female;&#xD;
&#xD;
          -  Patients with reproductive potential who do not agree to practice acceptable methods&#xD;
             of birth control throughout the entire trial period, starting from signing the&#xD;
             informed consent and up to 6 months after the last dose of GNR-051;&#xD;
&#xD;
          -  Simultaneous participation in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Svetlana B. Korotkova, MD, PhD</last_name>
    <phone>+7 9166816567</phone>
    <email>sbkorotkova@generium.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oksana A. Markova, MD, MSc</last_name>
    <phone>+7 9854418959</phone>
    <email>oamarkova@generium.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SAHI &quot;Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan&quot;</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;Leningrad Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Leningrad Region</city>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;N.N. Blokhin National Medical Research Center of Oncology&quot;of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Russian Scientific Center of Roentgenoradiology&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSAEI HE &quot;I.M. Sechenov First Moscow State Medical University&quot; of the Ministry of Health of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC &quot;MEDSI&quot; Group of Companies&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>123056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSII &quot;Treatment and Rehabilitation Center&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;N.N. Petrov National Medical Research Center of Oncology&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Modern Medical Technologies&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSAEI HE &quot;I.P. Pavlov First Saint Petersburg State Medical University&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Tentanda Via&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Carcinoma, Renal Cell</keyword>
  <keyword>Urologic Neoplasms</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Antineoplastic Agents, Immunological</keyword>
  <keyword>Kidney Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

